Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Oncology
314 Articles Available
1
14
Can't find what you're looking for? Try our
advanced search
.
FDA Approval
Sandoz Receives FDA Approval for Oncology Supportive Care Biosimilar Ziextenzo™
PR-M11-19-NI-006
Strategic Collaboration
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
PR-M10-19-NI-048
Containment
Meeting the Need for Higher Containment
PAP-Q3-19-CL-025
Genomics Technology
Personalizing Cancer Treatment with Genomics Technology
PAP-Q3-19-CL-018
FDA Guidance
Updating Ethical Guidelines for Cancer Clinical Trials
PAP-Q3-19-NI-006
FDA Priority Review
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
PR-M10-19-NI-025
Research
Viagra Helps Mobilize Bone Marrow Stem Cells for Transplantation in Mice
PR-M10-19-NI-018
Oncology
Blood Test Can Replace Invasive Biopsy for More Patients with Lung Cancer
PR-M09-19-NI-059
Liquid Biopsy
GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study
PR-M09-19-NI-058
DataArt’s Healthcare & Life Sciences Practice Launches “SkinCareAI” Prototype App for Early Melanoma Detection
PR-M09-19-NI-054
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
PR-M09-19-NI-007
Collaboration
Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology
PR-M09-19-NI-002
Recovering from Cancer Treatment May Get Easier
Announcement
GSK Announces Positive Headline Results from the Pivotal DREAMM-2 Study for Multiple Myeloma
PR-M08-19-NI-075
CAR-T
Pact Pharma Believes It Can Develop CAR T-Cell Therapies for Solid Tumors
PAO-M08-19-NI-020
Leadership
GSK Grows Oncology Pipeline Under CSO’s Leadership
PAO-M08-19-NI-018
Oncology
PARP Inhibitors May Be Useful for Treating More Cancers
PAO-M08-19-NI-016
Oncology
Tagrisso Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-Mutated Non-Small Cell Lung Cancer
PR-M08-19-NI-041
Virtual Research
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
PR-M08-19-NI-041
Oncology
Genentech’s Tecentriq® (ATEZOLIZUMAB) Reduced the Risk of Disease Worsening or Death in Advanced Bladder Cancer
PR-M08-19-NI-031
Clinical Data
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
PR-M08-19-NI-015
Legal
Celgene to pay Mylan $62 Million to Resolve Cancer Drug Antitrust Case
PR-M08-19-NI-007
Engineered Bacteria
Tackling Solid Tumors with Engineered Bacteria
PAO-M08-19-NI-007
Oncology
Roche Receives CHMP Positive Opinion for New Tecentriq-based Combination Therapy as an Initial Treatment for Most Common Form of Advanced Lung Cancer
PR-M08-19-NI-004
1
14
»
